Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future

被引:1486
作者
Kahn, Steven E. [1 ]
Cooper, Mark E. [2 ]
Del Prato, Stefano [3 ]
机构
[1] Univ Washington, VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA
[2] Baker IDI Heart & Diabet Inst, Diabet Div, Melbourne, Vic, Australia
[3] Univ Pisa, Sch Med, Dept Clin & Expt Med, I-56100 Pisa, Italy
基金
英国医学研究理事会;
关键词
BETA-CELL FUNCTION; GLUCAGON-LIKE PEPTIDE-1; LIFE-STYLE INTERVENTION; IMPAIRED GLUCOSE-TOLERANCE; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; FIBROBLAST GROWTH-FACTORS; INSULIN-TREATED PATIENTS; ACTING BASAL INSULIN; ALL-CAUSE MORTALITY;
D O I
10.1016/S0140-6736(13)62154-6
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Glucose metabolism is normally regulated by a feedback loop including islet beta cells and insulin-sensitive tissues, in which tissue sensitivity to insulin affects magnitude of beta-cell response. If insulin resistance is present, beta cells maintain normal glucose tolerance by increasing insulin output. Only when beta cells cannot release sufficient insulin in the presence of insulin resistance do glucose concentrations rise. Although beta-cell dysfunction has a clear genetic component, environmental changes play an essential part. Modern research approaches have helped to establish the important role that hexoses, aminoacids, and fatty acids have in insulin resistance and beta-cell dysfunction, and the potential role of changes in the microbiome. Several new approaches for treatment have been developed, but more effective therapies to slow progressive loss of beta-cell function are needed. Recent findings from clinical trials provide important information about methods to prevent and treat type 2 diabetes and some of the adverse effects of these interventions. However, additional long-term studies of drugs and bariatric surgery are needed to identify new ways to prevent and treat type 2 diabetes and thereby reduce the harmful effects of this disease.
引用
收藏
页码:1068 / 1083
页数:16
相关论文
共 202 条
[1]
LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys [J].
Adams, Andrew C. ;
Halstead, Carolyn A. ;
Hansen, Barbara C. ;
Irizarry, Armando R. ;
Martin, Jennifer A. ;
Myers, Sharon R. ;
Reynolds, Vincent L. ;
Smith, Holly W. ;
Wroblewski, Victor J. ;
Kharitonenkov, Alexei .
PLOS ONE, 2013, 8 (06)
[3]
Sirtuin activators [J].
Alcain, Francisco J. ;
Villalba, Jose M. .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2009, 19 (04) :403-414
[4]
[Anonymous], IDF DIAB ATL UPD 201
[5]
[Anonymous], NEW ENGL J MED
[6]
[Anonymous], 1970, Diabetes, V19, P747
[7]
[Anonymous], DIABETES CA IN PRESS
[8]
[Anonymous], 2013, ASS REP GLP 1 BAS TH
[9]
[Anonymous], 2012, BMJ Clin Evid
[10]
Effects of Metformin, Metformin Plus Rosiglitazone, and Metformin Plus Lifestyle on Insulin Sensitivity and β-cell Function in TODAY [J].
Arslanian, Silva ;
Pyle, Laura ;
Payan, Marisa ;
Bacha, Fida ;
Caprio, Sonia ;
Haymond, Morey W. ;
Levitsky, Lynne L. ;
Goland, Robin ;
White, Neil H. ;
Willi, Steven M. .
DIABETES CARE, 2013, 36 (06) :1749-1757